PRKAA2 and osteosarcoma: ATO exerts anti-osteosarcoma effects by inhibiting UBE2O-mediated L3MBTL2 degradation, while arborinine blocks UBE2O’s degradation of substrates like AMPKα2 and demonstrates synergistic chemotherapeutic potential in breast and liver cancer models.